Stifel is a full-service investment bank with deep industry experience. We serve as strategic advisors to entrepreneurs, family-owned businesses, private equity groups, and leading public and private corporations in North America, Europe, Asia, and Latin America. Our full-service healthcare investment banking practice offers a best-in-class combination of deep sector knowledge, strong industry relationships, and broad product expertise. We are not bound by borders. We stand ready to provide the insight and expertise you require. Our integrated approach allows us to deliver the full capabilities of Stifel’s institutional capital markets platform and retail brokerage network, which are among the most highly regarded in the industry.

At Lilly, we take smart risks on bold science to achieve our mission of bringing life-changing medicines to patients. As a community of scientists, we understand the brilliance and dedication this work takes. We also recognize our responsibility as partners to help advance life-changing medicines within our walls and beyond. More than 100 years ago, we pioneered strategic collaborations to scale the bold work of four University of Toronto research scientists to launch the world’s first commercial insulin. We're proud to continue our legacy in collaboration, with ~50% of our new product launches in the last 10 years enabled by external innovation, and over 70 active alliances with the vibrant academic and biotech ecosystem.  We know that every partnership is different - from stage, modality, therapeutic area, and culture. We have the skill, capabilities, and know-how to bring a holistic suite of models to life to continuously meet your needs. Let’s grow together!

InvestHK’s vision is to strengthen Hong Kong’s status as the leading international finance and business hub. Our mission is facilitate and promote economically and strategically important investment, both inward and outward, to support the economic development of Hong Kong.

Our purpose is to reimagine medicine to improve and extend people's lives. We use innovative science and technology to address some of society's most challenging healthcare issues. We discover and collaborate with innovators to develop breakthrough treatments finding new ways to deliver them to as many people as possible. Our vision: To become the most valued and trusted medicines company in the world Our strategy: Our strategy is to deliver high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches. 4 Core Therapeutic Areas: cardiovascular, renal and metabolic, immunology, neuroscience and oncology 2+3 Technology Platforms: Chemistry, Biotherapeutics, xRNA, Radioligand Therapy (RLT), and Cell & Gene Therapy Partnering is at the core of our business meaningfully contributing to our purpose to extend and improve people's lives. Our focused strategy to deliver high-value medicines comes with a renewed partnering effort. As the Corporate & Business Development team we've reshaped how we collaborate - we have a unified strategy fueled by clarity, agility, accountability, and efficiency. We welcome innovation, no matter where it originates or the development cycle you're at.

Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk and Novonesis and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Principal Investments, Planetary Health Investments and Asia teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2023, Novo Holdings had total assets of EUR 149 billion.

An economic powerhouse situated on the border of three countries, Basel-Stadt offers a very dynamic business environment. A healthy ecosystem thrives on its diversity to enrich and pollinate each other. Existing blue-chip companies, international companies that settle here, leading research institutes and SME’s rub shoulders with vibrant startups, prolific incubators and multinationals which thrive in the area. Born in the nucleus of life sciences innovation, Basel-Stadt flourishes as an international hub of innovation, culture and business acumen. Switzerland is considered the most innovative country in the world, according to a number of studies. Access to knowledge, highly qualified and international talent and a supportive government have turned Basel into the leading innovation hub of Switzerland. A future-oriented outlook with continuous innovation marks Basel as an international leader in life sciences, healthcare, ICT technology and circular economy. With a population of 200,000, Basel may seem to be a small city, but its rich economic and cultural offerings put it firmly in the big league. Many international companies and well-known brands such as Novartis, Roche, Lonza, Moderna, BeiGgene, Bayer and Syngenta have their headquarters here, and the city has a thriving, multi-cultural, well-educated expat community coming from more than 160 different countries.